4-EA-NBOMe
4-EA-NBOMe법적 상태 | |
---|---|
법적 상태 |
|
식별자 | |
| |
PubChem CID | |
화학 및 물리 데이터 | |
공식 | C19H25NO |
몰 질량 | 283.415 g/120−1 |
3D 모델(JSmol) | |
| |
|
4-EA-NBOMe는 치환 암페타민 및 25-NB 유도체로, 디자이너 의약품으로 판매되고 있다.2014년 [1]독일의 한 법의학 연구소에 의해 처음 확인되었지만, 분석 특성과 신진대사가 [2][3][4]연구되고 있지만, 약리학은 아직 알려지지 않았다.
「 」를 참조해 주세요.
레퍼런스
- ^ "EMCDDA–Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2015.
- ^ Westphal F, Girreser U, Waldmüller D (September 2016). "Analytical characterization of four new ortho-methoxybenzylated amphetamine-type designer drugs". Drug Testing and Analysis. 8 (9): 910–9. doi:10.1002/dta.1889. PMID 26606897.
- ^ Caspar AT, Westphal F, Meyer MR, Maurer HH (January 2018). "LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques". Analytical and Bioanalytical Chemistry. 410 (3): 897–912. doi:10.1007/s00216-017-0526-0. PMID 28762065. S2CID 206923339.
- ^ Caspar AT, Meyer MR, Maurer HH (March 2018). "Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach". Toxicology Letters. 285: 1–8. doi:10.1016/j.toxlet.2017.12.017. PMID 29277574.